# Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

> **NCT04855305** · PHASE2 · COMPLETED · sponsor: **Bastiaan Driehuys** · enrollment: 46 (actual)

## Conditions studied

- Interstitial Lung Diseases

## Interventions

- **DRUG:** Hyperpolarized 129Xe

## Key facts

- **NCT ID:** NCT04855305
- **Lead sponsor:** Bastiaan Driehuys
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-12
- **Primary completion:** 2025-06-11
- **Final completion:** 2025-06-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855305, "Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04855305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*